A citizen from Hangzhou, East China's Zhejiang Province, experiences the brain-computer interface slow-wave deep sleep conditioning technology on March 19, 2026. Photo: VCG

China's brain-computer interface (BCI) industry has made fresh headway, with many provinces having set government-guided prices for BCI-related procedures, with the prices for invasive BCI implantation ranging from 6,000 yuan ($879.15) to 6,600 yuan per procedure. A number of BCI companies also posted fresh progress in recent days.

According to an article on the website of the National Healthcare Security Administration on Thursday, the move will help stabilize the expected market returns for innovative enterprises.

In one latest process made by the industry, NeuroXess, a Shanghai-based BCI company, announced on Thursday a key breakthrough in its second clinical trial, following the successful implantation of its first fully implanted, fully wireless, fully functional BCI at the end of 2025, the Securities Times reported. 

By deeply integrating 50-millisecond ultra-low full-link latency with BCI-driven functional electrical stimulation technology, the system enabled a 29-year-old art teacher with high-level paraplegia to eat independently and create paintings, according to the report. 

NeuroXess said that the breakthrough demonstrates that the technology has officially entered a new phase of clinical practicality and replicable scalability, laying a solid foundation for large-scale application.

In March, the National Medical Products Administration approved the world's first invasive BCI medical device. The equipment is intended for patients who suffer from quadriplegia caused by cervical spinal cord injuries and are unable to perform grasping movements with their fingers, the Xinhua News Agency reported.

Against this backdrop, more companies are entering the field. On Wednesday, Lepu Medical announced during its earnings call that its non-invasive BCI-related products have already generated revenue, and animal trials of its interventional multi-channel BCI product have been completed, with the product having entered the next-phase clinical research stage, according to yicai.com.

Yicai.com reported that financing for BCI companies has boomed since 2025, citing an industry report.

In 2025 alone, about 25 financing events took place, with total funds raised standing at almost 1.45 billion yuan. In the first quarter of 2026, there were 17 financing events, which raised more than in all of 2025.

In March, Shanghai-based Stairmed announced a strategic funding round of 500 million yuan, led by Alibaba and followed by Tencent, marking the deep entry of internet giants into the BCI sector.